Cargando…

Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease(MAFLD)

BACKGROUND: Some studies found that red blood cell count (RBC) was an unrecognized risk factor for non-alcoholic fatty liver disease (NAFLD). While the epidemiological data underpinning the evidence is very limited. As there are some differences between the latest criteria of metabolic dysfunction-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Xinyi, Zhou, Guowei, Xu, Luzhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794081/ https://www.ncbi.nlm.nih.gov/pubmed/36574367 http://dx.doi.org/10.1371/journal.pone.0279274

Ejemplares similares

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

A43 SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
por: Kablawi, D, et al.
Publicado: (2023)

Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023)

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
por: Barranco-Fragoso, Beatriz, et al.
Publicado: (2022)

FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population
por: Gu, Zhan, et al.
Publicado: (2020)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
por: Yao, Nan, et al.
Publicado: (2022)

What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)
por: Bril, Fernando
Publicado: (2021)

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
por: Kaya, Eda, et al.
Publicado: (2022)

Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
por: Zhao, Jianan, et al.
Publicado: (2021)

Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD)
por: Heebøll, Sara, et al.
Publicado: (2022)

Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
por: Buzova, Diana, et al.
Publicado: (2020)

Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)—A Review
por: Różański, Gracjan, et al.
Publicado: (2021)

Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
por: Vos, Dyonne Y., et al.
Publicado: (2021)

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
por: Drożdż, Karolina, et al.
Publicado: (2021)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017–2018
por: Tian, Ting, et al.
Publicado: (2022)

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
por: Yang, Keungmo, et al.
Publicado: (2023)

Altered Mitochondrial Quality Control in Rats with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Induced by High-Fat Feeding
por: Cioffi, Federica, et al.
Publicado: (2022)

Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation
por: Zakaria, Zaida, et al.
Publicado: (2021)

Influence of Altered Thyroid Hormone Mechanisms in the Progression of Metabolic Dysfunction Associated with Fatty Liver Disease (MAFLD): A Systematic Review
por: Marschner, Rafael Aguiar, et al.
Publicado: (2022)

Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis
por: Liao, Yudi, et al.
Publicado: (2023)

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
por: Badmus, Olufunto O., et al.
Publicado: (2022)

Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients: A Prospective Cohort Study
por: Billeter, Adrian T., et al.
Publicado: (2022)

Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis
por: Lutsiv, Tymofiy, et al.
Publicado: (2023)

Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
por: Estévez-Vázquez, Olga, et al.
Publicado: (2021)

From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
por: Flisiak-Jackiewicz, Marta, et al.
Publicado: (2021)

Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2022)

The Diagnostic and Prognostic Value of the Triglyceride-Glucose Index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Systematic Review and Meta-Analysis
por: Wang, Jing, et al.
Publicado: (2022)

The Intestinal Microbiome and the Metabolic Syndrome—How Its Manipulation May Affect Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Malnick, Stephen D. H., et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Is Associated with Cervical Stromal Involvement in Endometrial Cancer Patients: A Cross-Sectional Study in South China
por: Lin, Xite, et al.
Publicado: (2023)

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
por: Abou Assi, Reem, et al.
Publicado: (2021)

Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran
por: Taheri, Ehsaneh, et al.
Publicado: (2021)

Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome?
por: Milivojević, Vladimir, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hmvplc75c23s5vsmjkui3ac6tq